

Program	Investigational treatment	Disease	Target patient	Study name	Sites	Dose finding / safety run-in	Proof-of-concept	Registration	Approved
Savolitinib MET	Savolitinib + Tagrisso	NSCLC	2L/3L EGFRm; Tagrisso ref.; MET+	SAVANNAH	Global	*			
	Savolitinib + Tagrisso	NSCLC	2L/3L EGFRm; Tagrisso ref.; MET+	SAFFRON	Global	**			
	Savolitinib + Imfinzi (PD-1)	Papillary RCC	MET+	SAMETA	Global				
	Savolitinib + Imfinzi (PD-1)	Papillary RCC	All	CALYPSO	UK/Spain	***			
	Savolitinib	Gastric cancer	MET+	VIKTORY	S Korea	***			
	Savolitinib	NSCLC	MET Exon 14 skipping		China				Marketed
	Savolitinib + Tagrisso	NSCLC	Naive MET+ & EGFRm NSCLC	SANOVO	China				
	Savolitinib + Tagrisso	NSCLC	2L EGFR TKI ref. NSCLC; MET+	SACHI	China				
Savolitinib	Gastric cancer	2L; MET+		China					
Surufatinib VEGFR 1/2/3; FGFR 1; CSF-1R	Surufatinib	NET	Refractory		US				
	Surufatinib	NET	Refractory		EU				MAA under review
	Surufatinib	NET			JP	(Bridging)			
	Surufatinib + tislelizumab (PD-1)	Solid tumors			US/EU				
	Surufatinib	Pancreatic NET	All	SANET-p	China				Marketed
	Surufatinib	Non-Pancreatic NET	All	SANET-ep	China				Marketed
	Surufatinib + Tuoyi (PD-1)	NEC		SURTORI-01	China				
	Surufatinib + Tuoyi (PD-1)	ESCC			China				
	Surufatinib + Tuoyi (PD-1)	GC, SCLC			China				
	Surufatinib + Tuoyi (PD-1)	BTC, Sarcoma			China				
Surufatinib + Tuoyi (PD-1)	TC, EMC, NSCLC			China					
Fruquintinib VEGFR 1/2/3	Fruquintinib	Colorectal cancer	Refractory	FRESCO-2	US/EU/JP				
	Fruquintinib	Breast cancer			US				
	Fruquintinib + tislelizumab (PD-1)	TN breast cancer, EMC			US				
	Fruquintinib + tislelizumab (PD-1)	Solid tumors			S Korea				
	Fruquintinib	Colorectal cancer	≥3L; chemotherapy refractory	FRESCO	China				Marketed
	Fruquintinib + Taxol	Gastric cancer	2L	FRUTIGA	China				
	Fruquintinib + Tyvyt (PD-1)	EMC			China				
	Fruquintinib + Tyvyt (PD-1)	CRC			China				
	Fruquintinib + Tyvyt (PD-1)	RCC, HCC			China				
	Fruquintinib + Tyvyt (PD-1)	GI tumors			China				
Fruquintinib + tislelizumab (PD-1)	Solid tumors			China					
Amdizalisib (HMPL-689) PI3Kδ	Amdizalisib	Indolent NHL, PTCL			US/EU				
	Amdizalisib	Healthy volunteers			Australia				
	Amdizalisib	FL			China				
	Amdizalisib	MZL			China				
	Amdizalisib	MCL, DLBCL			China				
	Amdizalisib	CLL/SLL, HL			China				
Sovleplenib (HMPL-523) Syk	Sovleplenib	Indolent NHL			Australia				
	Sovleplenib	Indolent NHL			US/EU				
	Sovleplenib	ITP	All	ESLIM-01	China				
	Sovleplenib	B-cell malignancies	All		China				
	Sovleplenib	wAIHA	All		China	**			
Tazemetostat EZH2	Tazemetostat ****	FL	Relapsed/Refractory	SYMPHONY-1	China	**			
	Tazemetostat ****	FL	3L		China	** (Bridging)			
<i>Note: Tazemetostat developed by Epizyme. Approved in the U.S. for ES and FL as a monotherapy. HUTCHMED rights are for Greater China – bridging study being planned.</i>									
HMPL-453 FGFR 1/2/3	HMPL-453	IHCC			China				
	HMPL-453	Solid tumors	Multiple combos		China				
HMPL-306 IDH 1/2	HMPL-306	Solid tumors			US/EU				
	HMPL-306	Heme. malignancies			US/EU				
	HMPL-306	Heme. malignancies			China				
HMPL-295 ERK, MAPK pathway	HMPL-295	Solid tumors			China				
HMPL-760 BTK, 3G	HMPL-760	B-Cell NHL			US/EU	**			
	HMPL-760	B-Cell NHL			China				
HMPL-653 CSF-1R	HMPL-653	Solid tumors, TGCT			China				